Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1Breast Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Letrozole 31Fulvestrant 30Specimen Handling 28pembrolizumab 22ribociclib 20Magnetic Resonance Spectroscopy 19Trastuzumab 18Paclitaxel 18palbociclib 17Capecitabine 17Anastrozole 17exemestane 15abemaciclib 15Biopsy 15pertuzumab 14Tamoxifen 14Carboplatin 14trastuzumab deruxtecan 11Cyclophosphamide 10Taxes 8Radiotherapy 8Goserelin 8inavolisib 6giredestrant 6atezolizumab 6Standard of Care 6Nivolumab 6Gemcitabine 6Docetaxel 6Aromatase Inhibitors 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
taxane × Breast × 30 days × Clear all
NCT07578116 2026-05-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

SWOG Cancer Research Network

Phase 3 Not yet recruiting
562 enrolled
Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡